Clinical Takeaway
People who use cannabis and have both PTSD and a substance use disorder still benefit meaningfully from trauma-focused treatments, with outcomes comparable to those who do not use cannabis. This finding supports offering evidence-based, trauma-focused care to this population rather than withholding or delaying it due to cannabis use.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by examining whether trauma-focused treatments maintain efficacy in patients with comorbid PTSD and substance use disorders who also use cannabis, a population often excluded from efficacy trials. The findings clarify treatment selection and outcome expectations for the substantial proportion of trauma survivors with polysubstance use, directly informing clinical decision-making and patient counseling in real-world settings. Understanding differential treatment response in cannabis-using patients with PTSD+SUD has significant implications for reducing the clinical uncertainty that currently limits evidence-based treatment implementation in this high-risk, under-studied population.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis provides valuable individual-level data on how cannabis use may influence trauma-focused treatment outcomes in patients with comorbid PTSD and substance use disorders, several important limitations warrant careful interpretation. The analysis draws from only four RCTs within a larger Project Harmony dataset, which constrains generalizability and may not capture the full spectrum of cannabis use patterns, potency levels, or concurrent medications that could modify treatment response. Trauma-focused therapies remain evidence-based interventions for PTSD regardless of cannabis use status, yet this work appropriately prompts us to consider whether baseline cannabis use or continued use during treatment may require individualized treatment planning, enhanced monitoring, or adjunctive motivational interventions to optimize outcomes. Clinically, patients with co-occurring PTSD, cannabis use, and other substance use disorders should not be excluded from gold-standard trauma-focused treatments, but providers should assess cannabis use patterns at baseline and throughout therapy, normalize discussion of use as part of PTSD symptom management and
| |